Abbott Laboratories Taps Morgan Stanley To Help Sell Established Drugs
Abbott Laboratories (ABT.N) is considering selling a big chunk of its mature drugs, joining a list of large drugmakers seeking to sell their older products in an effort to focus on high-growth areas, people familiar with the matter said. Abbott's portfolio of mature drugs being reviewed for sale has around $2 billion in annual revenue and could fetch more than $5 billion, the people said. The U.S. drugmaker is working with Morgan Stanley (MS.N) to find a buyer for the off-patent, or established products, the people added, asking not to be identified because the matter is confidential.
Help employers find you! Check out all the jobs and post your resume.